MYQORZO
What is MYQORZO?
MYQORZO is a medication used to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle becomes abnormally thick and blocks the blood flow. MYQORZO is part of a newer type of medications called cardiac myosin inhibitors, which target the underlying cause of cardiovascular disease instead of only treating symptoms.
Why is MYQORZO Important?
Hypertrophic cardiomyopathy poses a serious threat to patients, causing life-threatening arrhythmias and significantly increasing the risk of sudden cardiac death. MYQORZO relaxes the heart muscle and reduces blood obstruction, improving blood flow throughout the body for patients with oHCM.
Clinical Trial Results:
Patients in a 2024 SEQUOIA-HCM clinical trial took MYQORZO and showed significant improvements in exercise performance, symptom reduction, and heart activity compared to placebo groups.
Symptoms of MYQORZO:
Dizziness
Fatigue
High blood pressure
Shortness of breath
One major concern is reduced heart pumping function, which patients would need regular echocardiograms during treatment.
Cost & Accessibility:
According to a healthcare report published in 2025, MYQORZO approximately cost $108,400 a year in the United States without insurance, making this medication unaffordable for underserved communities. Insurance and patient assistance programs may help reduce the cost for eligible patients.
MYQORZO is one of the most recent FDA approved medications in treating obstructive hypertrophic cardiomyopathy. This medication represents major advancements in cardiovascular care, as it is able to manage symptoms and target the underlying disease. Even though the medication improves the quality of life and heart function for many patients, it requires careful monitoring and remains costly for many Americans. Please consult a medical professional if you have any further questions about MYQORZO.
